纽约大学研究员获美国国立卫生研究院拨款，优化CAR-T细胞癌治疗!，相信这个问题是许多正在准备留学的同学关心的一个问题，那么下面小编就来和大家说一说，感兴趣的您赶紧往下了解吧。

　　纽约大学研究员获美国国立卫生研究院（National Institutes of Health）拨款，优化CAR-T细胞癌治疗

　　BROOKLYN, New York, Monday, October 28, 2019 –Weiqiang Chen, assistant professor of biomedical engineering and mechanical and aerospace engineering at the NYU Tandon School of Engineering, has been awarded the Maximizing Investigators’ Research Award (R35) from the National Institute of General Medical Sciences, a pision of the National Institutes of Health (NIH). The five-year, $1.7 million grant will support Chen’s lab’s efforts to devise engineering-based methods for understanding and improving the efficacy of immunotherapy treatment for cancer.

　　2019年10月28日，星期一，纽约布鲁克林区——纽约大学TANDUN工程学院生物医学工程和机械与航空工程助理教授Weiqiang Chen被授予国立医学研究所最大的研究者研究奖（R35），美国国立卫生研究院的一个部门。这项为期5年、170万美元的拨款将支持陈的实验室努力设计基于工程的方法，以了解和提高癌症免疫治疗的疗效。

　　Chen, who heads NYU Tandon’s Applied Micro-Bioengineering Laboratory, explained that the grant will advance three key areas of interdisciplinary research aimed at developing personalized approaches to CAR-T cell therapy, a rapidly advancing cancer treatment modality that can produce remarkable results in select patients, yet carries significant risks.

　　纽约大学坦顿应用微生物工程实验室的负责人陈解释说，这项拨款将推进跨学科研究的三个关键领域，旨在开发个性化的car-t细胞治疗方法，这是一种快速发展的癌症治疗方法，可以在选定的患者身上产生显著的效果，但也具有重要风险。

　　The funds will support the continued development of Chen’s microfluidic “organ on a chip” systems to model disease environments and study cell interactions. This approach, which uses cells from inpidual cancer patients to create personalized, in-vitro disease models, can quickly provide key information about the potential efficacy of treatment methods—including CAR-T—against a patient’s own cancer. “Once you try a cancer therapy, it can take six months to know if it’s working,” said Chen. “By studying the interactions between tumor cells and T-cells in-vitro, we can determine if a patient is likely to be responsive in just two weeks, and our system allows us to test 10 or more treatments in parallel to find the best option.”

　　这些资金将支持陈的微流控“芯片上的器官”系统的持续发展，以模拟疾病环境和研究细胞间的相互作用这种方法利用单个癌症患者的细胞创建个性化的体外疾病模型，可以快速提供关于治疗方法（包括CAR-T）对患者自身癌症的潜在疗效的关键信息“一旦你尝试癌症治疗，可能需要6个月才能知道它是否有效，”陈说“通过在体外研究肿瘤细胞和T细胞之间的相互作用，我们可以确定患者是否可能在两周内产生反应，我们的系统允许我们同时测试10种或更多的治疗方法，以找到最佳选择。”

　　Leukemia-on-a-Chip cancer microenvironment uses cells from inpidual cancer patients to create personalized, in-vitro disease models, which can quickly provide key information about the potential efficacy of treatment methods.

　　白血病芯片上的癌症微环境利用单个癌症患者的细胞创建个性化的体外疾病模型，可以快速提供有关治疗方法潜在疗效的关键信息。

　　Chen’s research, which blends engineering and medicine, is also probing the mechanical forces at play during interactions between immune cells and cancer cells, particularly during the process by which the former kills the later. Additionally, in a study published recently in the journal Advanced Materials, Chen described a novel mechanical system for measuring how local stress on a cell causes physical changes that could flag chronic diseases. He noted that there are force-mediated changes in T-cell morphology that facilitate their attachment to cancer cells, and additional forces applied as immune cells eradicate tumor cells. Through this novel investigation into the mechanobiology of CAR-T cells, Chen and his collaborators hope to illuminate, and eventually optimize, the cell mechanics involved in these interactions.

　　陈的研究将工程学和医学结合在一起，同时也在探索免疫细胞和癌细胞之间的相互作用过程中，特别是前者杀死后者的过程中所发挥的机械力。此外，在最近发表在《先进材料》杂志上的一项研究中，陈描述了一种新的机械系统，用于测量细胞局部应力如何导致可能标志慢性疾病的物理变化。他指出，在T细胞形态上有力介导的改变，有助于它们附着在癌细胞上，而在免疫细胞消灭肿瘤细胞时也有额外的力通过对CAR-T细胞机制生物学的新研究，陈和他的合作者希望阐明并最终优化参与这些相互作用的细胞机制。

　　Finally, the grant will advance a longstanding area of Chen’s work—the development of biosensors capable of measuring chemical communication between cells. In this case, Chen aims to create sensors to detect and measure the biochemicals that facilitate communication between immune cells and tumor cells during CAR-T cell therapy.

　　最后，这项拨款将推动陈的一项长期工作，即开发能够测量细胞间化学通讯的生物传感器在这种情况下，陈的目标是创建传感器来检测和测量在car-t细胞治疗期间促进免疫细胞和肿瘤细胞之间通信的生化物质。

　　The R35 is Chen’s second award from the National Institutes of Health. Last year Chen received the National Institute of Biomedical Imaging and Bioengineering Trailblazer R21 Award for a lab-on-a-chip system for testing immunotherapy for glioblastoma, “Engineered Glioblastoma Tumor Immunity for Personalized Immunotherapy.”

　　R35是陈在国立卫生研究院获得的第二个奖项。去年，陈获得了国家生物医学成像与生物工程研究所（National Institute of Biomedical Imaging and BioEngineering Trailzer R21）颁发的胶质母细胞瘤免疫检测芯片系统“工程化胶质母细胞瘤肿瘤免疫个性化免疫治疗”奖。

　　Earlier this month, he was one of just 12 researchers to be named a 2019 Young Innovator by the Biomedical Engineering Society.

关于纽约大学研究员获美国国立卫生研究院拨款，优化CAR-T细胞癌治疗!这个问题本文的分享就到这里结束了，如果您还想了解更多相关的内容，那么可以持续关注本频道。

>>免费领全球留学白皮书，了解各大学报考条件、费用、开学时间、含金量<<